Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells

Breast Cancer Research and Treatment

Volumn 109, Issue 2, 2008, Pages 241-250

  Hodges Gallagher, Leslie ^a,b   Valentine, Cathleen D ^a   Bader, Suzy El ^a   Kushner, Peter J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Combithera Inc ^*  (United States)

Author keywords

Antiestrogens; Breast cancer; Estrogen receptor beta; Fulvestrant; Raloxifene; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR BETA; FULVESTRANT; HISTONE DEACETYLASE; RALOXIFENE; SOMATOMEDIN C RECEPTOR;

APOPTOSIS; ARTICLE; BIK GENE; BREAST CANCER; CANCER CELL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN TARGETING;

APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR MODULATORS; FEMALE; FLOW CYTOMETRY; HELA CELLS; HUMANS; IMMUNOBLOTTING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 43149093785     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9640-6     Document Type: Article

References (48)

1. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339(8784):1-15
2. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114):1451-1467
3. Clarke R, Leonessa F, Welch JN et al (2001) Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53(1):25-71
4. Ring A, Dowsett M (2004) Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11(4):643-658
5. Hopp TA, Weiss HL, Parra IS et al (2004) Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 10(22):7490-7499
6. Iwase H, Zhang Z, Omoto Y et al (2003) Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. Cancer Chemother Pharmacol 52(Suppl 1):S34-S38
7. Mann S, Laucirica R, Carlson N et al (2001) Estrogen receptor beta expression in invasive breast cancer. Hum Pathol 32(1):113-118
8. Murphy LC, Leygue E, Niu Y et al (2002) Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. Br J Cancer 87(12):1411-1416
9. Forster C, Makela S, Warri A et al (2002) Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proc Natl Acad Sci USA 99(24):15578-15583
10. Krege JH, Hodgin JB, Couse JF et al (1998) Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci USA 95(26):15677-15682
11. Bardin A, Boulle N, Lazennec G et al (2004) Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 11(3):537-551
12. Park BW, Kim KS, Heo MK et al (2003) Expression of estrogen receptor-beta in normal mammary and tumor tissues: is it protective in breast carcinogenesis? Breast Cancer Res Treat 80(1):79-85
13. Roger P, Sahla ME, Makela S et al (2001) Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 61(6):2537-2541
14. Shaaban AM, O'Neill PA, Davies MP et al (2003) Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol 27(12):1502-1512
15. Skliris GP, Munot K, Bell SM et al (2003) Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol 201(2):213-220
16. Murphy LC, Peng B, Lewis A et al (2005) Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J Mol Endocrinol 34(2):553-566
17. Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y et al (2003) Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene 22(32):5011-5020
18. Paruthiyil S, Parmar H, Kerekatte V et al (2004) Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 64(1):423-428
19. Strom A, Hartman J, Foster JS et al (2004) Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 101(6):1566-1571
20. Cowley SM, Hoare S, Mosselman S et al (1997) Estrogen receptors alpha and beta form heterodimers on DNA. J Biol Chem 272(32):19858-19862
21. Pettersson K, Grandien K, Kuiper GG et al (1997) Mouse estrogen receptor beta forms estrogen response element-binding heterodimers with estrogen receptor alpha. Mol Endocrinol 11(10):1486-1496
22. Hall JM, McDonnell DP (1999) The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140(12):5566-5578
23. Pettersson K, Delaunay F, Gustafsson JA (2000) Estrogen receptor beta acts as a dominant regulator of estrogen signaling. Oncogene 19(43):4970-4978
24. Liu MM, Albanese C, Anderson CM et al (2002) Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem 277(27):24353-24360
25. Paech K, Webb P, Kuiper GG et al (1997) Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277(5331):1508-1510
26. Webb P, Nguyen P, Valentine C et al (1999) The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol 13(10):1672-1685
27. Murphy LC, Watson PH (2006) Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer? Endocr Relat Cancer 13(2):327-334
28. Reid G, Hubner MR, Metivier R et al (2003) Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 11(3):695-707
29. Tateishi Y, Sonoo R, Sekiya Y et al (2006) Turning off estrogen receptor beta-mediated transcription requires estrogen-dependent receptor proteolysis. Mol Cell Biol 26(21):7966-7976
30. Agrawal A, Gutteridge E, Gee JM et al (2005) Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer 12(Suppl 1):S135-S144
31. Johnston SR (2005) Clinical trials of intracellular signal transductions inhibitors for breast cancer-a strategy to overcome endocrine resistance. Endocr Relat Cancer 12(Suppl 1):S145-S157
32. Moasser MM, Basso A, Averbuch SD et al (2001) The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61(19):7184-7188
33. Shou J, Massarweh S, Osborne CK et al (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96(12):926-935
34. Altucci L, Addeo R, Cicatiello L et al (1996) 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 12(11):2315-2324
35. Hodges LC, Cook JD, Lobenhofer EK et al (2003) Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Mol Cancer Res 1(4):300-311
36. Vermes I, Haanen C, Steffens-Nakken H et al (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184(1):39-51
37. Dong L, Wang W, Wang F et al (1999) Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells. J Biol Chem 274(45):32099-32107
38. Hodges-Gallagher L, Valentine CD, Bader SE et al (2006) Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells. Breast Cancer Res Treat (in press). DOI: 10.1007/s10549-006-9459-6
39. Hur J, Chesnes J, Coser KR et al (2004) The Bik BH3-only protein is induced in estrogen-starved and antiestrogen-exposed breast cancer cells and provokes apoptosis. Proc Natl Acad Sci USA 101(8):2351-2356
40. O'Neill PA, Davies MP, Shaaban AM et al (2004) Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers. Br J Cancer 91(9):1694-1702
41. Speirs V, Malone C, Walton DS et al (1999) Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res 59(21):5421-5424
42. Eeckhoute J, Carroll JS, Geistlinger TR et al (2006) A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev 20(18):2513-2526
43. Saji S, Hirose M, Toi M (2005) Clinical significance of estrogen receptor beta in breast cancer. Cancer Chemother Pharmacol 56(Suppl 1):21-26
44. Jang ER, Lim SJ, Lee ES et al (2004) The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene 23(9):1724-1736
45. Wang Y, Chirgadze NY, Briggs SL et al (2006) A second binding site for hydroxytamoxifen within the coactivator-binding groove of estrogen receptor beta. Proc Natl Acad Sci USA 103(26):9908-9911
46. Paige LA, Christensen DJ, Gron H et al (1999) Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc Natl Acad Sci USA 96(7):3999-4004
47. Webb P, Valentine C, Nguyen P et al (2003) ERbeta binds N-CoR in the presence of estrogens via an LXXLL-like motif in the N-CoR C-terminus. Nucl Recept 1(1):4
48. Wong CW, Komm B, Cheskis BJ (2001) Structure-function evaluation of ER alpha and beta interplay with SRC family coactivators. ER selective ligands. Biochemistry 40(23):6756-6765